CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

← UNITED STATES ANTIMONY CORP (UAMY) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫

UNITED STATES ANTIMONY CORP (UAMY)

Primary Smelting & Refining of Nonferrous Metals · market cap $693M · as of 2026-07-20

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst
None scheduled
Pipeline
1
programs
Upcoming events
0
next 90d+
Dossier
Ready
cached
United States Antimony Corp (UAMY) is a primary smelting and refining company for nonferrous metals with a market cap of ~$809M and a share price of ~$5.46. Despite its industrial metals operating business — which generated $39M in revenue in 2025 — the company also carries a Phase 2 HIV-1 asset (UB-421) whose mechanism is undisclosed in available data. The financial position is critically strained, with only $3.4M cash and an estimated runway of under one month.
The catalyst path

No upcoming catalysts in our calendar.

Pipeline
AssetPhaseIndication
UB-421Phase 2HIV-1 Infection
Price & technical context
3-month
-30.1%
6-month
-50.5%
12-month
-28.8%
52-wk range
$4.49–$17.47
vs 50-day MA
-13.9%
vs 200-day MA
-39.6%
Realized vol
130.4%
Max drawdown
-74.3%

Daily closes through 2026-09-23. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

Sources & data
  • SEC filings — EDGAR filings for UAMY (10-K, 10-Q, S-3, 13D/G, Form 4)
  • Clinical trials — 1 registered trial on ClinicalTrials.gov (per-trial NCT links in the pipeline)
  • Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
  • Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.